Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 838 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection; Drug · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Glioblastoma
Interventions: CART-EGFR-IL13Ra2 cells, Rituximab or Rituximab biosimilar, Fludarabine + Cyclophosphamide combination; Drug · Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2042
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
Interventions: HER3-DXd; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
U.S. locations: 21
States / cities: Springdale, Arkansas • Los Angeles, California • Aurora, Colorado + 16 more

Conditions: Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell, Carcinoma, Large Cell
Interventions: PF-02341066/PF-00299804; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma
Interventions: ONC201; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing, Pharmacokinetic sampling - simvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Dacomitinib, Osimertinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Pemetrexed, Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 17
States / cities: Duarte, California • Orange, California • Santa Monica, California + 13 more

Conditions: Gastric Cancer, Stomach Cancer
Interventions: Cetuximab, Irinotecan, Cisplatin, Surgery, 5-FU, Radiation; Drug · Procedure · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastric Cancer, Precancerous Condition
Interventions: Cetuximab; Biological
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Interventions: BCA101, Pembrolizumab; Drug
Lead sponsor: Bicara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions: NEOK002, NEOK002 RDE; Drug
Lead sponsor: NEOK Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Orlando, Florida • New York, New York • Nashville, Tennessee + 5 more

Conditions: Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
Interventions: BLU-701, osimertinib, carboplatin, pemetrexed; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more

Conditions: Solid Tumor, NSCLC
Interventions: JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib; Drug
Lead sponsor: Allist Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 12 more

Conditions: EGFR Inhibitor-associated Rash
Interventions: Menadione Topical Lotion; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Vallejo, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions: assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 113
States / cities: Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
Interventions: INIPARIB + irinotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Kidney Transplant; Complications
Interventions: Finerenone Oral Tablet, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
Interventions: Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate, Pharmacological Study, Therapeutic Conventional Surgery; Other · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions: Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer
Interventions: AUY922; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Acneiform Rash, Papulopustular Eruption
Interventions: Triamcinolone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer
Interventions: ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Tucson, Arizona • Cerritos, California • San Francisco, California + 5 more

Search by objective public record fields.

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

Medical Access Program for Patritumab Deruxtecan

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors